Biologic Therapies Targeting Eosinophils: Current Status and Future Prospects

Journal of Allergy and Clinical Immunology: In Practice

Volumn 3, Issue 2, 2015, Pages 167-174

  Legrand, Fanny ^a   Klion, Amy D ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Asthma; Benralizumab; Eosinophilic gastrointestinal disorders; Hypereosinophilic syndrome; MAb; Mepolizumab; Reslizumab

Indexed keywords

ALTRAKINCEPT; BENRALIZUMAB; BERTILIMUMAB; BIOLOGICAL PRODUCT; COMPLEMENT COMPONENT C3; DUPILUMAB; EOTAXIN; EPIDERMAL GROWTH FACTOR LIKE MODULE CONTAINING MUCIN LIKE HORMONE RECEPTOR 1; HORMONE RECEPTOR; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 25; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 5 RECEPTOR ALPHA; LEBRIKIZUMAB; MEPOLIZUMAB; OMALIZUMAB; PASCOLIZUMAB; PLACEBO; PREDNISONE; RESLIZUMAB; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN 8; THYMIC STROMAL LYMPHOPOIETIN; TRALOKINUMAB; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ALLERGIC REACTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; ATOPIC DERMATITIS; BINDING AFFINITY; BULLOUS PEMPHIGOID; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTITIS; DISEASE EXACERBATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DUODENITIS; EOSINOPENIA; EOSINOPHIL; EOSINOPHIL ASSOCIATED DISEASE; EOSINOPHIL COUNT; EOSINOPHILIA; EOSINOPHILIC ESOPHAGITIS; EOSINOPHILIC GASTRITIS; EOSINOPHILIC GASTROENTERITIS; EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; HUMAN; HYPEREOSINOPHILIC SYNDROME; IMMUNOMODULATION; LEUKOCYTE DISORDER; MASTOCYTOSIS; NONHUMAN; NOSE POLYP; SINGLE DRUG DOSE; TREATMENT OUTCOME; ULCERATIVE COLITIS; URTICARIA; ANIMAL; BIOLOGICAL THERAPY; IMMUNE SYSTEM DISEASES; IMMUNOLOGY;

ANIMALS; BIOLOGICAL THERAPY; EOSINOPHILS; HUMANS; IMMUNE SYSTEM DISEASES; INTERLEUKIN-5;

EID: 84924187758     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2015.01.013     Document Type: Article

References (85)

1. Bochner B.S., Book W., Busse W.W., Butterfield J., Furuta G.T., Gleich G.J., et al. Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD). JAllergy Clin Immunol 2012, 130:587-596.
2. Hekking P.P., Bel E.H. Developing and emerging clinical asthma phenotypes. JAllergy Clin Immunol Pract 2014, 2:671-680.
3. Ogbogu P.U., Bochner B.S., Butterfield J.H., Gleich G.J., Huss-Marp J., Kahn J.E., et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. JAllergy Clin Immunol 2009, 124:1319-1325.e3.
4. Pelaia G., Vatrella A., Maselli R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov 2012, 11:958-972.
5. Wechsler M.E., Fulkerson P.C., Bochner B.S., Gauvreau G.M., Gleich G.J., Henkel T., et al. Novel targeted therapies for eosinophilic disorders. JAllergy Clin Immunol 2012, 130:563-571.
6. Gleich G.J., Klion A.D., Lee J.J., Weller P.F. The consequences of not having eosinophils. Allergy 2013, 68:829-835.
7. Fulkerson P.C., Rothenberg M.E. Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov 2013, 12:117-129.
8. Radonjic-Hoesli S., Valent P., Klion A.D., Wechsler M.E., Simon H.U. Novel targeted therapies for eosinophil-associated diseases and allergy. Annu Rev Pharmacol Toxicol 2015, 55:633-656.
9. Sanderson C.J. Eosinophil differentiation factor (interleukin-5). Immunol Ser 1990, 49:231-256.
10. Mauser P.J., Pitman A.M., Fernandez X., Foran S.K., Adams G.K., Kreutner W., et al. Effects of an antibody to interleukin-5 in a monkey model of asthma. Am J Respir Crit Care Med 1995, 152:467-472.
11. Hart T.K., Cook R.M., Zia-Amirhosseini P., Minthorn E., Sellers T.S., Maleeff B.E., et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. JAllergy Clin Immunol 2001, 108:250-257.
12. Kips J.C., O'Connor B.J., Langley S.J., Woodcock A., Kerstjens H.A., Postma D.S., et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003, 167:1655-1659.
13. Leckie M.J., ten Brinke A., Khan J., Diamant Z., O'Connor B.J., Walls C.M., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 356:2144-2148.
14. Flood-Page P., Swenson C., Faiferman I., Matthews J., Williams M., Brannick L., et al. Astudy to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007, 176:1062-1071.
15. Haldar P., Brightling C.E., Hargadon B., Gupta S., Monteiro W., Sousa A., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. NEngl J Med 2009, 360:973-984.
16. Nair P., Pizzichini M.M., Kjarsgaard M., Inman M.D., Efthimiadis A., Pizzichini E., et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. NEngl J Med 2009, 360:985-993.
17. Haldar P., Brightling C.E., Singapuri A., Hargadon B., Gupta S., Monteiro W., et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. JAllergy Clin Immunol 2014, 133:921-923.
18. Castro M., Mathur S., Hargreave F., Boulet L.P., Xie F., Young J., et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011, 184:1125-1132.
19. Pavord I.D., Korn S., Howarth P., Bleecker E.R., Buhl R., Keene O.N., et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012, 380:651-659.
20. Ortega H., Li H., Suruki R., Albers F., Gordon D., Yancey S. Cluster analysis and characterization of response to mepolizumab: a step closer to personalized medicine for patients with severe asthma. Ann Am Thorac Soc 2014, 11:1011-1017.
21. Prazma C.M., Wenzel S., Barnes N., Douglass J.A., Hartley B.F., Ortega H. Characterisation of an OCS-dependent severe asthma population treated with mepolizumab. Thorax 2014, 69:1141-1142.
22. Ortega H.G., Liu M.C., Pavord I.D., Brusselle G.G., FitzGerald J.M., Chetta A., et al. Mepolizumab treatment in patients with severe eosinophilic asthma. NEngl J Med 2014, 371:1198-1207.
23. Bel E.H., Wenzel S.E., Thompson P.J., Prazma C.M., Keene O.N., Yancey S.W., et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. NEngl J Med 2014, 371:1189-1197.
24. Bjermer L., Lemiere C., Maspero J., Ciesielska M., O'Brien C., Zangrilli J. Arandomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils. Eur Respir J 2014, 44. abstract#299.
25. Corren J., Weinstein S., Janka L., O'Brien C., Zangrilli J. Arandomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma. Eur Respir J 2014, 44. abstract#4673.
26. Valent P., Gleich G.J., Reiter A., Roufosse F., Weller P.F., Hellmann A., et al. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol 2012, 5:157-176.
27. Plotz S.G., Simon H.U., Darsow U., Simon D., Vassina E., Yousefi S., et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. NEngl J Med 2003, 349:2334-2339.
28. Garrett J.K., Jameson S.C., Thomson B., Collins M.H., Wagoner L.E., Freese D.K., et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. JAllergy Clin Immunol 2004, 113:115-119.
29. Klion A.D., Law M.A., Noel P., Kim Y.J., Haverty T.P., Nutman T.B. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 2004, 103:2939-2941.
30. Rothenberg M.E., Klion A.D., Roufosse F.E., Kahn J.E., Weller P.F., Simon H.U., et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. NEngl J Med 2008, 358:1215-1228.
31. Roufosse F., de Lavareille A., Schandene L., Cogan E., Georgelas A., Wagner L., et al. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. JAllergy Clin Immunol 2010, 126. 828-35.e3.
32. Roufosse F.E., Kahn J.E., Gleich G.J., Schwartz L.B., Singh A.D., Rosenwasser L.J., et al. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. JAllergy Clin Immunol 2013, 131. 461-7.e1-5.
33. Boucher R.M., Gilbert-McClain L., Chowdhury B. Hypereosinophilic syndrome and mepolizumab. NEngl J Med 2008, 358:2838-2839. author reply 9-40.
34. Kahn J.E., Grandpeix-Guyodo C., Marroun I., Catherinot E., Mellot F., Roufosse F., et al. Sustained response to mepolizumab in refractory Churg-Strauss syndrome. JAllergy Clin Immunol 2010, 125:267-270.
35. Kim S., Marigowda G., Oren E., Israel E., Wechsler M.E. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. JAllergy Clin Immunol 2010, 125:1336-1343.
36. Moosig F., Gross W.L., Herrmann K., Bremer J.P., Hellmich B. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med 2011, 155:341-343.
37. Herrmann K., Gross W.L., Moosig F. Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome. Clin Exp Rheumatol 2012, 30:S62-S65.
38. Stein M.L., Collins M.H., Villanueva J.M., Kushner J.P., Putnam P.E., Buckmeier B.K., et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. JAllergy Clin Immunol 2006, 118:1312-1319.
39. Straumann A., Conus S., Grzonka P., Kita H., Kephart G., Bussmann C., et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 2010, 59:21-30.
40. Spergel J.M., Rothenberg M.E., Collins M.H., Furuta G.T., Markowitz J.E., Fuchs G., et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. JAllergy Clin Immunol 2012, 129:456-463. 463.e1-3.
41. Assa'ad A.H., Gupta S.K., Collins M.H., Thomson M., Heath A.T., Smith D.A., et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology 2011, 141:1593-1604.
42. Phipps S., Flood-Page P., Menzies-Gow A., Ong Y.E., Kay A.B. Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin. JInvest Dermatol 2004, 122:1406-1412.
43. Oldhoff J.M., Darsow U., Werfel T., Katzer K., Wulf A., Laifaoui J., et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005, 60:693-696.
44. Oldhoff J.M., Darsow U., Werfel T., Bihari I.C., Katzer K., Laifaoui J., et al. No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients. Int Arch Allergy Immunol 2006, 141:290-294.
45. Gevaert P., Lang-Loidolt D., Lackner A., Stammberger H., Staudinger H., Van Zele T., et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. JAllergy Clin Immunol 2006, 118:1133-1141.
46. Murata Y., Takaki S., Migita M., Kikuchi Y., Tominaga A., Takatsu K. Molecular cloning and expression of the human interleukin 5 receptor. JExp Med 1992, 175:341-351.
47. Sanderson C.J. Interleukin-5, eosinophils, and disease. Blood 1992, 79:3101-3109.
48. Liu L.Y., Sedgwick J.B., Bates M.E., Vrtis R.F., Gern J.E., Kita H., et al. Decreased expression of membrane IL-5 receptor alpha on human eosinophils, I: loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge. JImmunol 2002, 169:6452-6458.
49. Wilson T.M., Maric I., Shukla J., Brown M., Santos C., Simakova O., et al. IL-5 receptor alpha levels in patients with marked eosinophilia or mastocytosis. JAllergy Clin Immunol 2011, 128. 1086-92.e1-3.
50. Kolbeck R., Kozhich A., Koike M., Peng L., Andersson C.K., Damschroder M.M., et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. JAllergy Clin Immunol 2010, 125. 1344-53.e2.
51. Busse W.W., Katial R., Gossage D., Sari S., Wang B., Kolbeck R., et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. JAllergy Clin Immunol 2010, 125. 1237-44.e2.
52. Laviolette M., Gossage D.L., Gauvreau G., Leigh R., Olivenstein R., Katial R., et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. JAllergy Clin Immunol 2013, 132. 1086-96.e5.
53. Brightling C.E., Bleecker E.R., Panettieri R.A., Bafadhel M., She D., Ward C.K., et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2014, 2:891-901.
54. Castro M., Wenzel S.E., Bleecker E.R., Pizzichini E., Kuna P., Busse W.W., et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014, 2:879-890.
55. Nowak R.M., Parker J.M., Silverman R.A., Rowe B.H., Smithline H., Khan F., et al. Arandomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma. Am J Emerg Med 2015, 33:14-20.
56. Neves J.S., Perez S.A., Spencer L.A., Melo R.C., Reynolds L., Ghiran I., et al. Eosinophil granules function extracellularly as receptor-mediated secretory organelles. Proc Natl Acad Sci U S A 2008, 105:18478-18483.
57. Ying S., Robinson D.S., Meng Q., Rottman J., Kennedy R., Ringler D.J., et al. Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma: association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur J Immunol 1997, 27:3507-3516.
58. Ben S., Li X., Xu F., Xu W., Li W., Wu Z., et al. Treatment with anti-CC chemokine receptor 3 monoclonal antibody or dexamethasone inhibits the migration and differentiation of bone marrow CD34 progenitor cells in an allergic mouse model. Allergy 2008, 63:1164-1176.
59. Bochner B.S. Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors. Clin Exp Allergy 2009, 39:317-324.
60. Kiwamoto T., Kawasaki N., Paulson J.C., Bochner B.S. Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. Pharmacol Ther 2012, 135:327-336.
61. Nutku E., Aizawa H., Hudson S.A., Bochner B.S. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 2003, 101:5014-5020.
62. Na H.J., Hamilton R.G., Klion A.D., Bochner B.S. Biomarkers of eosinophil involvement in allergic and eosinophilic diseases: review of phenotypic and serum markers including a novel assay to quantify levels of soluble Siglec-8. JImmunol Methods 2012, 383:39-46.
63. Munitz A., Bachelet I., Levi-Schaffer F. Reversal of airway inflammation and remodeling in asthma by a bispecific antibody fragment linking CCR3 to CD300a. JAllergy Clin Immunol 2006, 118:1082-1089.
64. Hamann J., Koning N., Pouwels W., Ulfman L.H., van Eijk M., Stacey M., et al. EMR1, the human homolog of F4/80, is an eosinophil-specific receptor. Eur J Immunol 2007, 37:2797-2802.
65. Legrand F., Tomasevic N., Simakova O., Lee C.C., Wang Z., Raffeld M., et al. The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disorders. JAllergy Clin Immunol 2014, 133:1439-1447. 1447.e1-8.
66. Massanari M., Holgate S.T., Busse W.W., Jimenez P., Kianifard F., Zeldin R. Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respir Med 2010, 104:188-196.
67. Busse W., Spector S., Rosen K., Wang Y., Alpan O. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. JAllergy Clin Immunol 2013, 132:485-486.
68. Foroughi S., Foster B., Kim N., Bernardino L.B., Scott L.M., Hamilton R.G., et al. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. JAllergy Clin Immunol 2007, 120:594-601.
69. Clayton F., Fang J.C., Gleich G.J., Lucendo A.J., Olalla J.M., Vinson L.A., et al. Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE. Gastroenterology 2014, 147:602-609.
70. Kopf M., Le Gros G., Bachmann M., Lamers M.C., Bluethmann H., Kohler G. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993, 362:245-248.
71. Fulkerson P.C., Schollaert K.L., Bouffi C., Rothenberg M.E. IL-5 triggers a cooperative cytokine network that promotes eosinophil precursor maturation. JImmunol 2014, 193:4043-4052.
72. Hart T.K., Blackburn M.N., Brigham-Burke M., Dede K., Al-Mahdi N., Zia-Amirhosseini P., et al. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol 2002, 130:93-100.
73. Borish L.C., Nelson H.S., Lanz M.J., Claussen L., Whitmore J.B., Agosti J.M., et al. Interleukin-4 receptor in moderate atopic asthma: a phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999, 160:1816-1823.
74. Corren J., Lemanske R.F., Hanania N.A., Korenblat P.E., Parsey M.V., Arron J.R., et al. Lebrikizumab treatment in adults with asthma. NEngl J Med 2011, 365:1088-1098.
75. Piper E., Brightling C., Niven R., Oh C., Faggioni R., Poon K., et al. Aphase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2013, 41:330-338.
76. Noonan M., Korenblat P., Mosesova S., Scheerens H., Arron J.R., Zheng Y., et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. JAllergy Clin Immunol 2013, 132. 567-74.e12.
77. Wenzel S., Ford L., Pearlman D., Spector S., Sher L., Skobieranda F., et al. Dupilumab in persistent asthma with elevated eosinophil levels. NEngl J Med 2013, 368:2455-2466.
78. Beck L.A., Thaci D., Hamilton J.D., Graham N.M., Bieber T., Rocklin R., et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. NEngl J Med 2014, 371:130-139.
79. Corren J., Busse W., Meltzer E.O., Mansfield L., Bensch G., Fahrenholz J., et al. Arandomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010, 181:788-796.
80. Rothenberg M.E., Wen T., Greenberg A., Alpan O., Enav B., Hirano I., et al. Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. JAllergy Clin Immunol 2014 Sep 13, pii: S0091-6749(14)01053-7. http://dx.doi.org/10.1016/j.jaci.2014.07.049. [Epub ahead of print].
81. Rosenberg H.F., Dyer K.D., Foster P.S. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol 2013, 13:9-22.
82. Yu S., Kim H.Y., Chang Y.J., DeKruyff R.H., Umetsu D.T. Innate lymphoid cells and asthma. JAllergy Clin Immunol 2014, 133:943-950. quiz 51.
83. Sherrill J.D., Gao P.S., Stucke E.M., Blanchard C., Collins M.H., Putnam P.E., et al. Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitis. JAllergy Clin Immunol 2010, 126:160-165.
84. Gauvreau G.M., O'Byrne P.M., Boulet L.P., Wang Y., Cockcroft D., Bigler J., et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. NEngl J Med 2014, 370:2102-2110.
85. Busse W.W., Holgate S., Kerwin E., Chon Y., Feng J., Lin J., et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 2013, 188:1294-1302.